Cyramza(ramucirumab)
Cyramza (ramucirumab) is an antibody pharmaceutical. Ramucirumab was first approved as Cyramza on 2014-04-21. It is used to treat colorectal neoplasms, non-small-cell lung carcinoma, and stomach neoplasms in the USA. It has been approved in Europe to treat stomach neoplasms. The pharmaceutical is active against vascular endothelial growth factor receptor 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Cyramza
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cyramza | Biologic Licensing Application | 2025-01-27 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| colorectal neoplasms | — | D015179 | — |
| non-small-cell lung carcinoma | — | D002289 | — |
| stomach neoplasms | EFO_0003897 | D013274 | C16 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
ramucirumab, Cyramza, Eli Lilly and Company | |||
| 2026-05-10 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9308 | Injection, ramucirumab, 5 mg |
Clinical
Clinical Trials
176 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 7 | 13 | 3 | — | — | 20 |
| Adenocarcinoma | D000230 | — | — | 5 | 8 | 5 | — | 2 | 17 |
| Lung neoplasms | D008175 | — | C34.90 | 4 | 11 | 3 | — | — | 16 |
| Carcinoma | D002277 | — | C80.0 | 4 | 7 | 3 | — | — | 13 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 2 | 4 | 3 | — | 2 | 10 |
| Esophageal neoplasms | D004938 | — | C15 | — | 7 | 3 | — | 1 | 10 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 3 | 3 | 2 | — | — | 7 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 3 | 3 | 2 | — | — | 7 |
| Colorectal neoplasms | D015179 | — | — | 2 | 2 | 2 | — | — | 6 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 2 | 1 | — | — | 5 |
Show 3 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 11 | 8 | — | — | — | 18 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 2 | — | — | — | 3 |
| Squamous cell carcinoma | D002294 | — | — | 1 | 3 | — | — | — | 3 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | 2 | — | — | — | 2 |
| Melanoma | D008545 | — | — | 1 | 1 | — | — | — | 2 |
| Biliary tract neoplasms | D001661 | — | C24.9 | 1 | 1 | — | — | — | 2 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | 2 | — | — | — | 2 |
| Sarcoma | D012509 | — | — | 1 | 1 | — | — | — | 1 |
| Synovial sarcoma | D013584 | — | — | 1 | 1 | — | — | — | 1 |
| Urethral neoplasms | D014523 | EFO_0003846 | — | — | 1 | — | — | — | 1 |
Show 16 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Microsatellite instability | D053842 | — | — | 1 | — | — | — | — | 1 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 1 | — | — | — | — | 1 |
| Central nervous system neoplasms | D016543 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ramucirumab |
| INN | ramucirumab |
| Description | Ramucirumab (human mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1743062 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB05578 |
| UNII ID | D99YVK4L0X (ChemIDplus, GSRS) |
Target
Agency Approved
KDR
KDR
Organism
Homo sapiens
Gene name
KDR
Gene synonyms
FLK1, VEGFR2
NCBI Gene ID
Protein name
vascular endothelial growth factor receptor 2
Protein synonyms
CD309, Fetal liver kinase 1, fetal liver kinase-1, FLK-1, KDR, Kinase insert domain receptor, kinase insert domain receptor (a type III receptor tyrosine kinase), Protein-tyrosine kinase receptor flk-1, soluble VEGFR2, tyrosine kinase growth factor receptor
Uniprot ID
Mouse ortholog
Kdr (16542)
vascular endothelial growth factor receptor 2 (Q8VCD0)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Cyramza – Eli Lilly
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,502 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,149 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use